MEDVi Tirzepatide Pricing Explained: First-Month Rate vs Refill Costs

Last reviewed: September 4, 2026 Last updated: September 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

MEDVi offers compounded tirzepatide at a first-month introductory price of $279, then charges $399 per month for every refill (verified September 4, 2026). Over 12 months, a new patient pays $4,668 total—$279 for the first shipment plus 11 refills at $399 each—yielding an effective monthly average of $389. An existing patient paying only the refill rate spends $4,788 annually ($399 × 12 months). Both figures include medication, consult, unlimited support, and shipping, with no separate membership fee and no contract. PlexusDx charges $289 per month month-to-month or $249 per month on a six-month commitment for compounded tirzepatide injection, translating to $3,468 or $2,988 over 12 months—a difference of $1,200 to $1,800 compared to MEDVi's structure (our calculation, September 4, 2026).

MEDVi vs PlexusDx tirzepatide at a glance

MEDVi pricing verified September 4, 2026; PlexusDx pricing verified July–September 2026. Twelve-month totals are our calculation.

Understanding MEDVi's introductory-plus-refill pricing

MEDVi structures its compounded tirzepatide program with a first-month introductory rate of $279, then transitions to a standard refill price of $399 per month beginning with the second shipment. The introductory rate applies only to the initial order; every subsequent four-week supply carries the $399 refill price. Both figures include the provider consultation, compounded medication, unlimited support access, and shipping, with no separate membership fee. MEDVi advertises that dose increases do not raise the monthly price, and patients may cancel at any time without contract penalties (verified September 4, 2026).

For a new patient starting treatment, the effective cost over 12 months is $279 for month one plus 11 refills at $399 each, totaling $4,668—an average of $389 per month (our calculation). A patient already on treatment who pays only the refill rate spends $4,788 over 12 months, or $399 per month (our calculation). The difference between the two scenarios is the single $120 discount applied to the first shipment ($399 − $279 = $120).

PlexusDx tirzepatide: flat-rate structure with optional commitment tiers

PlexusDx charges $289 per month month-to-month for compounded tirzepatide injection, with no introductory period, no refill jump, and no membership fee. Patients who prefer price certainty and a lower rate may select a three-month commitment at $269 per month or a six-month commitment at $249 per month. All three tiers hold the same price regardless of dose, and every tier includes the provider visit, prescription, medication, and shipping. A free check-in with a Doctor of Pharmacy is available to all patients (verified July–September 2026).

Over 12 months, the month-to-month option totals $3,468; the three-month commitment totals $3,228; and the six-month commitment totals $2,988 (our calculation). PlexusDx publishes all pricing tiers on the product page before a patient begins the intake, and no separate refill rate applies after the first order.

Normalized 12-month cost comparison

To compare MEDVi's intro-plus-refill model against PlexusDx's flat-rate tiers, we calculate the total cost of 12 months of compounded tirzepatide under each scenario:

All totals are our calculation, derived from verified per-month rates captured July–September 2026.

Comparing month-to-month options, PlexusDx costs $1,200 less than MEDVi over 12 months for a new patient ($4,668 − $3,468), or $100 per month on average. Against MEDVi's refill-only scenario, the difference is $1,320 annually ($110 per month). Choosing PlexusDx's six-month commitment widens the gap to $1,680 saved versus MEDVi's new-patient total ($140 per month) or $1,800 saved versus MEDVi's refill-only total ($150 per month).

What the introductory rate means in practice

MEDVi's $279 first-month price reduces the barrier to starting tirzepatide, cutting the initial outlay by $120 compared to the standard $399 refill rate. For a patient who stays on treatment for exactly three months, the total cost is $279 + $399 + $399 = $1,077, or $359 per month on average. At six months, the total is $279 + (5 × $399) = $2,274, or $379 per month. At 12 months, the effective rate converges toward $389 per month, just $10 below the ongoing refill price.

The introductory discount is meaningful in month one but represents only 2.6 percent of the annual cost for a patient who remains on therapy for a full year (our calculation). The majority of long-term expense accrues at the $399 refill rate, making that figure—not the advertised first-month price—the relevant anchor for annual budgeting.

Inclusions, dose policy, and support

Both MEDVi and PlexusDx include the provider consultation, prescription (where PlexusDx explicitly lists it), medication, and shipping in the per-month price. Neither charges a separate membership or subscription fee. Both programs hold the same monthly price when a patient's dose increases, a policy that removes uncertainty as treatment progresses. MEDVi advertises unlimited support access; PlexusDx includes a free check-in with a Doctor of Pharmacy and offers an optional genetic-response testing add-on ($298 standalone, $99 for program members) for patients interested in DNA-guided medication data (verified July–September 2026).

MEDVi operates on a monthly refill cycle with no contract; patients may cancel at any time. PlexusDx offers month-to-month ordering or optional three- and six-month commitments that lower the per-month rate in exchange for upfront clarity on duration.

Review ratings: MEDVi and PlexusDx on Trustpilot

MEDVi holds a 4.3-star rating on Trustpilot with approximately 15,000 reviews (captured September 4, 2026). PlexusDx holds a 4.2-star rating, with 76 percent of reviews at five stars and 81 percent at four stars or higher (captured September 4, 2026). Both providers carry substantial review volume, and both ratings fall within the range typical of telehealth weight-management programs. Individual reports on any platform represent one patient's experience and should be read alongside aggregate rating distributions and the provider's published policies on refunds, pauses, and clinical escalation.

Compounding status and regulatory disclosure

MEDVi and PlexusDx both dispense compounded tirzepatide. Compounded medications are not FDA-approved. The FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Neither provider guarantees eligibility, dose, or treatment outcome. A licensed prescriber reviews each intake and may decline to prescribe or may recommend an alternative medication or dose based on medical history, contraindications, and clinical judgment.

Choose MEDVi if…

MEDVi may suit a patient who values a lower first-month cost and who is comfortable with the refill rate increasing to $399 beginning in month two. The introductory price reduces initial commitment, and the absence of a contract preserves the option to discontinue after one or two shipments without penalty. The program's unlimited support access and established Trustpilot presence (4.3 stars, ~15,000 reviews) offer reassurance for patients prioritizing customer-service track record over multi-year price predictability.

Choose PlexusDx if…

PlexusDx fits patients who prefer transparent, flat-rate pricing with no introductory period and no refill jump. The $289 month-to-month option costs $110 per month less than MEDVi's standard refill rate, saving $1,320 annually (our calculation). Patients planning six months or longer may lock in $249 per month, reducing the 12-month cost by $1,800 compared to MEDVi's refill-only scenario. The published commitment tiers, dose-invariant pricing, and free pharmacist check-in provide structure for patients who value cost certainty and clinical access without recurring surprises. PlexusDx's 4.2-star Trustpilot rating, with 81 percent of reviews at four stars or above, reflects consistent service execution across a verified review base.

Methodology and freshness

MEDVi pricing was verified through checkout on September 4, 2026, capturing both the advertised first-month introductory rate and the standard refill rate displayed at the payment step. PlexusDx pricing was verified on product pages and through intake flows between July 20, 2026, and September 4, 2026. Trustpilot ratings and review counts were captured on September 4, 2026. Twelve-month totals, effective monthly averages, and savings figures are our calculation, derived by multiplying verified per-month rates by the number of months in each scenario. We do not apply promotional codes, referral discounts, or discount arithmetic; every published price was observed directly in a checkout or product-page context. When evidence conflicts, we state the conflict and advise confirming at checkout. No conflict exists in the present dataset.

Frequently Asked Questions

Does MEDVi's introductory price apply every month?

No. MEDVi's $279 introductory rate applies only to the first shipment. Beginning with the second order, the price rises to $399 per month and remains at that level for all subsequent refills, as verified at checkout on September 4, 2026.

How much do I save over 12 months by choosing PlexusDx month-to-month instead of MEDVi?

PlexusDx's $289 month-to-month tirzepatide costs $3,468 over 12 months. MEDVi's structure (one $279 intro plus 11 refills at $399) totals $4,668. The difference is $1,200 saved annually, or $100 per month on average—our calculation from verified rates.

Can I lock in a lower rate at PlexusDx, and does it require prepayment?

Yes. PlexusDx offers a three-month commitment at $269 per month ($3,228 annually) and a six-month commitment at $249 per month ($2,988 annually). Commitments are billed monthly; you are not required to prepay the full term, but you agree to continue for the commitment period.

Do dose increases raise the monthly price at MEDVi or PlexusDx?

No. Both MEDVi and PlexusDx hold the same per-month rate across all tirzepatide doses. MEDVi explicitly states that dose adjustments do not change the $399 refill price, and PlexusDx publishes dose-invariant pricing on every product page, verified July–September 2026.

Are compounded tirzepatide and branded Zepbound the same medication?

No. Compounded tirzepatide is prepared by a compounding pharmacy and is not FDA-approved. Zepbound is the FDA-approved branded form of tirzepatide manufactured by Eli Lilly. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality before marketing. A licensed clinician determines whether a compounded prescription is appropriate based on individual patient factors.

Sources

• PlexusDx tirzepatide product page and intake flow (accessed July 20, 2026, and September 4, 2026)
• MEDVi pricing and checkout verification (accessed September 4, 2026)
• Trustpilot.com – MEDVi profile (accessed September 4, 2026)
• Trustpilot.com – PlexusDx profile (accessed September 4, 2026)

Compounded medication disclosure: Compounded medications are not FDA-approved. The FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.